GlassScriptPhysician profile
Adam H Feldman
NPI 1457331480
$34,089.57
in general payments reported to CMS, 2019-2025
21 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,608 · 2021: $11K · 2022: $8,003 · 2023: $1,164 · 2024: $600 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21,055.76 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $6,461.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $3,988.64 | 2019 | |
| Pfizer INC. | $763.01 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $603.32 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $250.42 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $185.76 | 2019-2025 | |
| Kaneka Medical America LLC | $151.05 | 2020 | |
| Boston Scientific Corporation | $146.34 | 2021 | |
| Heartflow, INC. | $98.65 | 2023-2024 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $95.54 | 2022-2025 | Farxiga, Brilinta |
| Scpharmaceuticals INC. | $62.36 | 2025 | |
| Atricure, INC. | $59.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.52 | 2019-2024 | Lifevest |
| Mannkind Corporation | $27.97 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $25.49 | 2019 | |
| Abbott Laboratories | $21.52 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.39 | 2023 | Inpefa |
| Siemens Medical Solutions USA, INC. | $18.29 | 2023 | C.Cam Imaging System |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.